Related Experiment Video

Updated: Apr 7, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K

miR-216a may inhibit pancreatic tumor growth by targeting JAK2

Bao-hua Hou1, Zhi-xiang Jian1, Peng Cui1

  • 1Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, PR China.

FEBS Letters
|July 8, 2015
PubMed

Insights

MicroRNA-216a (miR-216a) acts as a tumor suppressor in pancreatic cancer by targeting JAK2. Restoring miR-216a levels reduced tumor growth, suggesting its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic cancer is a leading cause of cancer-related mortality.
  • MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
  • Dysregulation of specific miRNAs, like miR-216a, is implicated in various cancers.

Purpose of the Study:

  • To investigate the expression of miR-216a in pancreatic cancer.
  • To determine the functional role of miR-216a in pancreatic cancer proliferation.
  • To identify the molecular targets of miR-216a in pancreatic cancer.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to assess miR-216a expression levels.
  • Bioinformatic analysis and luciferase reporter assays to identify miR-216a targets.
  • In vivo studies using PANC-1 pancreatic cancer xenografts in mice.

Main Results:

  • miR-216a was significantly downregulated in pancreatic cancer tissues compared to benign pancreatic lesions.
  • JAK2 was identified as a direct gene target of miR-216a.
  • In vivo administration of miR-216a mimic suppressed tumor growth and reduced JAK2 protein levels in PANC-1 xenografts.

Conclusions:

  • miR-216a functions as a tumor suppressor in pancreatic cancer.
  • miR-216a targets JAK2, potentially regulating the JAK/STAT signaling pathway.
  • miR-216a holds promise as a diagnostic biomarker and therapeutic agent for pancreatic cancer, warranting further clinical investigation.
Keywords:
ApoptosisCell proliferationJAK2Microarray miR-216aPancreatic cancer

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K
A Preclinical Murine Model of Hepatic Metastases06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

30.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K